Clinical trials: Ritonavir
HIV Infections
A Study to Compare Two Different Anti-HIV Drug Regimens
This study compares 2 different anti-HIV drug regimens to determine which is the most effective in lowering the amount of HIV in the blood.
- Trial name
- NCT00000924
- Testing
- Ritonavir, Nelfinavir mesylate, Nevirapine
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard…
- Trial name
- KALEAD (NCT00234910)
- Testing
- Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Abbott
AIDS-related Dementia Complex
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
The purpose of this study is to assess whether a boosting by cobicistat results in similar concentrations of darunavir in the brain compared to a boosting by ritonavir.
- Trial name
- NCT02503462
- Testing
- Darunavir, ritonavir, cobicistat
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- University Hospital, Basel, Switzerland
Human Immunodeficiency Virus
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.
- Trial name
- NCT00648999
- Testing
- lopinavir/ritonavir
- Where
- 13 sites in Mexico
- Volunteers
- 207 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
Steps I and II: The purpose of this study is the following: To look at how many patients achieve undetectable HIV blood levels at Week 16.
- Trial name
- NCT00001087
- Testing
- Ritonavir, Nelfinavir mesylate, Efavirenz
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Respiratory Failure
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure
Aim. The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide.
- Trial name
- CORMOR (NCT04388514)
- Testing
- Medical Ozone procedure
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
HIV Infection
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
This is an open label randomized clinial trial to evaluate the treatment with darunavir/ritonavir (800mg/100mg) plus lamivudine (300 mg) once daily versus continuing with darunavir/ritonavir (800mg/100mg) once daily plus…
- Trial name
- DUAL (NCT02159599)
- Testing
- Darunavir/Ritonavir, Lamivudine, Emtricitabine/tenofovir or abacavir/lamivudine
- Where
- 21 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Fundacion SEIMC-GESIDA
SARS CoV-2 Post-Acute Sequelae
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults.
- Trial name
- DEFEND (NCT06792214)
- Testing
- Nirmatrelvir/ritonavir, Remdesivir
- Where
- 4 sites in Canada
- Volunteers
- 118 people
- Sponsor
- Mount Sinai Hospital, Canada
Chronic Hepatitis C, Cirrhosis
Impact of Antiviral Therapy on Gastroesophageal Varices.
Hepatitis C virus (HCV) chronic infection affects 200 million people worldwide. HCV antiviral treatment has evolved rapidly since 2011.
- Trial name
- NCT02758509
- Testing
- Pegylated interferon alfa-2a + Ribavirin, Pegylated interferon alfa-2a + Ribavirin + Boceprevir, Pegylated interferon alfa-2a + Ribavirin +Telaprevir
- Volunteers
- 237 people
- Sponsor
- Parc de Salut Mar
Acquired Immune Deficiency Syndrome
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function better than regimens that do not contain…
- Trial name
- NCT00775606
- Testing
- Lopinavir 400 mg/ritonavir 100 mg, Efavirenz
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rush University Medical Center
HIV Infection
Safety and Efficacy Study of Switching From Epzicom to Truvada
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir…
- Trial name
- SWIFT (NCT00724711)
- Testing
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Healthy
Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers
Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)
- Trial name
- NCT02226978
- Testing
- Tipranavir, Ritonavir, Valaciclovir
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV, Tuberculosis
Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients
- Trial name
- NCT02415985
- Testing
- Lopinavir/r will be supplied by NHSO/GPO, Rifabutin
- Where
- 4 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
To compare the efficacy and safety of clarithromycin combined with rifabutin, ethambutol, or both in the treatment of disseminated Mycobacterium avium Complex (MAC) disease in persons with AIDS, including individuals who have or…
- Trial name
- NCT00001058
- Testing
- Indinavir sulfate, Ritonavir, Ethambutol hydrochloride
- Where
- 34 sites in United States, Tanzania
- Volunteers
- 246 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants
A study to evaluate safety, tolerability and pharmacokinetics of QLS1128 sustained-release tablets and in combination with ritonavir tablets in healthy participants
- Trial name
- NCT05458076
- Testing
- QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
HIV Infections
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing…
- Trial name
- NCT00006591
- Testing
- Ritonavir, Amprenavir
- Where
- United States
- Sponsor
- Gathe, Joseph, M.D.
COVID-19
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
The purpose of this study is to learn about: effects of living with COVID-19 and how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan.
- Trial name
- NCT06085924
- Testing
- SoC, Disease description
- Where
- Taiwan
- Volunteers
- 2,315,187 people
- Sponsor
- Pfizer
HIV Infections
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
To evaluate the relationship between viral suppression and changes in immune function, as measured by the restoration of delayed-type hypersensitivity (DTH) and lymphoproliferative (LP) responses, observed after 48 weeks of…
- Trial name
- NCT00000891
- Testing
- Ritonavir, Saquinavir, Delavirdine mesylate
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs.
- Trial name
- NCT00002239
- Testing
- Enfuvirtide, Ritonavir, Abacavir sulfate
- Where
- 20 sites in United States
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche